GNT Logo.png
GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients
September 08, 2021 06:00 ET | GNT Pharma Co., Ltd
PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomyFirst multi-target neuroprotectant for the intervention of ischemic brain injurySafety and efficacy verified in two...